SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Status:
RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.